organization · Reporting owner
GALEN PARTNERS III L P
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACURA PHARMACEUTICALS, INC
Report date December 14, 2017 · Filed January 02, 2018
Jointly reported with CLAUDIUS LLC, GALEN PARTNERS INTERNATIONAL III L P, GALEN EMPLOYEE FUND III LP, Galen Management, LLC
Section 16 reporting ended · disclosed 2018-01-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2017-12-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-12-14 · Sale · Disposed 2,195,734 · Balance 0 F1: The shares were sold in a private transaction pursuant to a stock purchase agreement by and among Galen Partners III, LP ("Galen III"), Galen Employee Fund III, LP, ("Employee Fund") Galen Partners International III, LP ("Galen International") and several purchasers. F2: The shares were sold as follows: 2,006,540 by Galen III, 180,928 by Galen International and 8,266 by Employee Fund. F3: Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold in a private transaction pursuant to a stock purchase agreement by and among Galen Partners III, LP ("Galen III"), Galen Employee Fund III, LP, ("Employee Fund") Galen Partners International III, LP ("Galen International") and several purchasers.
F2: The shares were sold as follows: 2,006,540 by Galen III, 180,928 by Galen International and 8,266 by Employee Fund.
F3: Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2017 Filed Jan 2, 2018 23:11 UTC | ACURA PHARMACEUTICALS, INC ACUR · Entity 69367 | SaleCommon Stock | 2,195,734 | $0.10 | $219,573.40 |
DisclosureSEC source: 0001209191-18-000346 · doc4.xml · nonDerivative · entry 1 CLAUDIUS LLC · CIK 0001056643 · Former 10% owner GALEN PARTNERS INTERNATIONAL III L P · CIK 0001034574 · Former 10% owner GALEN EMPLOYEE FUND III LP · CIK 0001056642 · Former 10% owner Galen Management, LLC · CIK 0001421162 · Former 10% owner GALEN PARTNERS III L P · CIK 0001034486 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The shares were sold in a private transaction pursuant to a stock purchase agreement by and among Galen Partners III, LP ("Galen III"), Galen Employee Fund III, LP, ("Employee Fund") Galen Partners International III, LP ("Galen International") and several purchasers. F2 · shares: The shares were sold as follows: 2,006,540 by Galen III, 180,928 by Galen International and 8,266 by Employee Fund. F3 · ownership.nature: Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Galen Management, L.L.C. serves as the sole General Partner of Employee Fund and has sole voting and investment control over the shares held by Employee Fund and may be deemed to beneficially own the shares held by Employee Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.